Amylin Pharmaceuticals (AMLN) Tops Q2 EPS by 2c
More News related to AMLN
- Canaccord Adams Reiterates Sell on Amylin (AMLN)
- Notable Analyst Rating Changes 9/2: AMLN, LOW, GOOG Upgraded; GILD, DF, NSC Downgraded
- Lazard Upgrades Amylin (AMLN) to Buy
- Top 10 News Items 8/25-8/29: Oil/Nat Gas See Volatile Trading on Gustav Concerns; Fannie/Freddie Nearly Double; FDIC Banking Profile Shows Worst Quarter Since '91
- BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) reports a Q2 loss of $0.47, 2 cents better than the analyst estimate of ($0.49). Revenues for the quarter were $222.0 million, versus the consensus of $224.26 million.
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States.
Related Categories
EarningsStocks Mentioned
-0.37Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
